Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Amneal Pharmaceuticals Inc (AMRX)

312 + Investors. Track Smart Money conviction in AMRX. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +42
Streak
3Q ▲
Buyers last Q
63%

Smart Money Signals — AMRX

Based on 314 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added AMRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
314 hedge funds hold AMRX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +35% more funds vs a year ago

fund count last 6Q
+82 new funds entered over the past year (+35% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟢

More buyers than sellers — 63% buying

196 buying114 selling
Last quarter: 196 funds were net buyers (79 opened a brand new position + 117 added to an existing one). Only 114 were sellers (77 trimmed + 37 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+24 vs last Q)

new funds entering per quarter
Funds opening a new AMRX position: 32 → 41 → 55 → 79. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

45% of holders stayed for 2+ years

■ 45% conviction (2yr+) ■ 23% medium ■ 32% new
142 out of 314 hedge funds have held AMRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
🚀

Acceleration phase — new buyers rushing in

56 → 32 → 41 → 55 → 79 new funds/Q
New funds entering each quarter: 32 → 41 → 55 → 79. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Deep conviction — 53% of holders stayed 2+ years

■ 53% veterans ■ 9% 1-2yr ■ 38% new
Of 316 current holders: 167 (53%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
✅

Strong quality — 33% AUM from major funds

33% from top-100 AUM funds
51 of 314 holders rank in the top 100 by AUM, accounting for 33% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.3
out of 10
Moderate Exit Risk
Exit risk score 4.3/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — AMRX

In 2026 Q1, 196 hedge funds were net buyers of AMRX (79 opened a new position, 117 added to an existing one), while 114 reduced or exited (77 trimmed, 37 sold completely) — a 63% buyer ratio, indicating clear institutional accumulation. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. 33% of total institutional value in AMRX is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +42 funds (more new holders than closures). Total institutional holders: 314.

Hedge Fund Ownership: AMRX

How many hedge funds hold AMRX — quarterly history vs. share price
Quarterly hedge fund ownership of AMRX vs. share price

Market Analysis: AMRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: AMRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Amneal Pharmaceuticals Inc (AMRX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much AMRX has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 79d ago
AMRX
+31.0%
XLV
+2.8%

AMRX outperformed XLV by +28.2% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 34d ago
AMRX
+36.5%
XLV
+3.9%

Since the filing became public, AMRX outperformed XLV by +32.6% .

Interpretation: The stock has significantly outperformed its sector benchmark — the original entry opportunity has largely been captured by earlier investors. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

33 top-rated funds 1 high-conviction
Consensus
6.6
/ 10
breadth
×
Elite
1.8
/ 10
conviction
Hedge Fund Positioning: AMRX
312 + Investors

Track Smart Money conviction in AMRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 312 272 14.71%
13F Shares 158M 154M 2.61%
Total Value $1.91B $1.94B -1.46%
New Positions 78 55 +23
Increased Positions 115 98 +17
Closed Positions 38 27 +11
Reduced Positions 76 81 -5
Total Calls 1 2 -50.0%
Total Puts 2 1 100.0%
PUT/CALL Ratio 2.0 0.5 Bearish

Statistics: AMRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

312 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in AMRX. Verified SEC 13F-HR filings.

QUARTER:
Top 25 AMRX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Westshore Wealth, LLC 5.99% 1,373,984 $17.1M
2 Tpg GP A, LLC 4.17% 12,328,767 $153.2M
3 Quartz Partners, LLC 2.15% 447,200 $5.6M
4 Phocas Financial Corp. 1.96% 1,002,664 $12.5M
5 BlackBarn Capital Partners LP 1.65% 1,650,000 $20.5M
6 Rubric Capital Management LP 1.45% 11,037,589 $137.2M
7 Nantahala Capital Management, LLC 1.30% 2,844,108 $35.4M
8 Penn Capital Management Company, LLC 1.15% 1,196,073 $14.9M
9 PFM Health Sciences, LP 1.05% 930,096 $11.6M
10 Freemont Management S.A. 0.60% 320,000 $4.0M
11 RPg Family Wealth Advisory, LLC 0.52% 200,092 $2.5M
12 Odyssean, LLC 0.51% 112,918 $1.4M
13 Parkman Healthcare Partners LLC 0.39% 300,752 $3.7M
14 Convergence Investment Partners, LLC 0.33% 164,314 $2.0M
15 Integrated Quantitative Investments LLC 0.32% 141,221 $1.8M
16 Oliver Luxxe Assets LLC 0.29% 156,285 $1.9M
17 Globeflex Capital L P 0.28% 146,303 $1.8M
18 Hillsdale Investment Management Inc. 0.25% 743,679 $9.2M
19 MQS Management LLC 0.22% 26,166 $325K
20 Voleon Capital Management LP 0.21% 786,764 $9.8M
21 Virtus Advisers, LLC 0.21% 35,921 $446K
22 Twinbeech Capital LP 0.17% 128,900 $1.6M
23 PDT Partners, LLC 0.13% 180,628 $2.2M
24 Occudo Quantitative Strategies LP 0.11% 152,007 $2.0M
25 Numerai GP LLC 0.10% 82,328 $1.0M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Amneal Pharmaceuticals Inc (AMRX)

What does the Smart Money Trend signal show for AMRX?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added AMRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for AMRX?

More buyers than sellers — 63% buying: Last quarter: 196 funds were net buyers (79 opened a brand new position + 117 added to an existing one). Only 114 were sellers (77 trimmed + 37 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for AMRX holders?

Strong quality — 33% AUM from major funds: 51 of 314 holders rank in the top 100 by AUM, accounting for 33% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held AMRX?

45% of holders stayed for 2+ years: 142 out of 314 hedge funds have held AMRX for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Amneal Pharmaceuticals Inc (AMRX) following the 2026 Q1 hedge fund 13F filings?

As of today, AMRX has moved +36.5% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of +32.6%. Since the quarter end (March 31, 2026), AMRX has gained +31.0% vs +2.8% for XLV. The stock has significantly outperformed its sector benchmark — the original entry opportunity has largely been captured by earlier investors.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →